Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. 7. Juni 2015 Hegewisch-Becker, S., Graeven, U., Lerchenmüller, C.A., Killing, B., Depenbusch, R., Steffens, C.-C., Al-Batran, S.-E., Lange, T., Dietrich, G., Stoehlmacher, J., Tannapfel, A., Reinacher-Schick, A., Quidde, J., Trarbach, T., Hinke, A., Schmoll, H.-J., Arnold, D., 2015. Lancet Oncol. 16, 1355–1369. doi:10.1016/S1470-2045(15)00042-X Abstract Efficacy of trastuzumab re-therapy in the clinical routine of HER2-positive breast cancer patients who relapsed after completed anti-HER2 (neo)adjuvant therapy with trastuzumab – 5th interim analysis of the national non-interventional study (NIS) ML21589. Hanker, L., Hitschold, T., Grafe, A., Förster, F., Schröder, J., Janssen, J., Reichert, D., Hielscher, C., Keitel, S., Hesse, T., 2015. Cancer Res 76 (4… Weiterlesen Progression-free and overall survival of patients with advanced or metastatic pancreatic cancer in German outpatient centers – first outcome data from the clinical TPK Registry. Hegewisch-Becker, S., Hofheinz, R., Wolf, T., Aldaoud, A., Harde, J., Kopfmann, S., Marschner, N., 2015. Oncol Res Treat 38 (suppl 5)(V26), 5. doi:10.1159/000439070… Weiterlesen